Ampliphi Biosciences Corp (NYSEAMERICAN:APHB) was the recipient of a large decline in short interest in the month of November. As of November 30th, there was short interest totalling 1,007,191 shares, a decline of 9.7% from the November 15th total of 1,115,468 shares. Currently, 10.7% of the shares of the company are short sold. Based on an average trading volume of 263,618 shares, the short-interest ratio is presently 3.8 days.

Shares of Ampliphi Biosciences (APHB) opened at $1.06 on Tuesday. Ampliphi Biosciences has a one year low of $0.67 and a one year high of $6.80.

Separately, HC Wainwright set a $5.00 target price on shares of Ampliphi Biosciences and gave the stock a “buy” rating in a report on Monday, October 2nd.

COPYRIGHT VIOLATION WARNING: “Ampliphi Biosciences Corp (APHB) Short Interest Update” was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another domain, it was illegally copied and republished in violation of U.S. & international trademark & copyright law. The legal version of this report can be read at https://www.americanbankingnews.com/2017/12/12/ampliphi-biosciences-corp-aphb-short-interest-update.html.

Ampliphi Biosciences Company Profile

AmpliPhi Biosciences Corporation is a biotechnology company. The Company is focused on the discovery, development and commercialization of phage therapeutics. The Company is engaged in identifying, characterizing and developing naturally occurring bacteriophages with its collaboration partners in bacteriophage biology, synthetic biology and manufacturing, to develop second-generation bacteriophage products.

Receive News & Ratings for Ampliphi Biosciences Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampliphi Biosciences Corp and related companies with MarketBeat.com's FREE daily email newsletter.